NeuroVive Pharmaceutical AB: First Patient Recruited to Clinical Phase II Study for Treatment of Traumatic Brain Injury

Published: Jun 05, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: NeuroVive Pharmaceutical AB (publ)(STO:NVP), a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the company´s drug candidate NeuroSTAT® for the treatment of traumatic brain injury. The trial is being conducted at the Department of Neurosurgery, Copenhagen University Hospital under the supervision of Professor Bertil Romner and Dr Walter Fischer. Bertil Romner is a leading expert in the treatment of traumatic brain injury, and Walter Fischer is the study’s principal investigator.

Help employers find you! Check out all the jobs and post your resume.

Back to news